JOWIN Co., Ltd. Signs Joint Research Agreement With ImpriMed Co., Ltd to Develop Optimal Anti-cancer Adjuvants

AI Precision Medicine Meets Traditional Cancer Treatment: JOWIN and ImpriMed Sign Joint Research Agreement

JOWIN Co., Ltd. (Chairman Kim Soo-Hyun,) and ImpriMed, a leading precision medicine AI technology company based in San Francisco, have signed a joint research agreement to develop optimal anticancer adjuvants.

At an agreement ceremony held in Seoul on the 28th of last month, both companies agreed to develop and identify anticancer adjuvants optimized for cancer patients by combining ImpriMed's advanced precision medicine AI model with JOWIN’s rich clinical observation capabilities through its nationwide cancer hospital network.

ImpriMed's AI technology is showing excellent results in analyzing living cancer cell-based bio-information of patients and suggesting personalized treatments. Meanwhile, JOWIN has accumulated years of experience in observational clinical research with natural anticancer minerals such as "Woonbijae(Micacine)" and anticancer substance Sulforaphane.

Kim Tae-Sik, an authority in intractable cancer research for 30 years and a director of JOWIN advisory committee, stated, "If this joint research and development yield results, it could be introduced not only in major hospitals in Korea but also in global cancer hospitals based on scientific data and clinical verification results," suggesting the potential for growth into a global K-medi company.

Despite the three major cancer treatments of modern medicine--surgery, chemotherapy, and radiation therapy--cancer related mortality remains the leading cause of death in many countries for decades. In this context, the development of a verified supplement that enhances anti-cancer effects and reduces side effects could not only aid in treatment but also prevent recurrence and cancer, potentially creating a market larger than the over 300 trillion Korean won anti-cancer drug market.

ImpriMed CEO Lim Sung-Won said, "I am pleased that combining precision medicine AI technology with JOWIN's clinical observation know-how in treating intractable cancer can contribute to finding the best supplements for cancer patients. We will do our best to maximize the synergy between the two companies to provide better treatment outcomes for cancer patients."

JOWIN Chairman Kim Soo-Hyun expressed, “We are very pleased to accelerate the development of new anticancer aids and verify existing substances through cooperation with ImpriMed,”  predicting that many anticancer substances and products, as well as traditional herbal-based anticare drugs, will yield significant results when combined with ImpriMed's AI technology and big data precision medicine.

The two companies have agreed to form a regular consultative body to monitor the progress of joint R&D and to cooperate in developing of natural treatments for specific cancer types that can be used alongside chemotherapy and radiation therapy. In addition, JOWIN plans to scientifically validate the anti-cancer effects of its recently introduced NK cell activation technology and high-frequency hyperthermia device “Cansalgi” using ImpriMed's AI technology.

JOWIN Co., Ltd. announced that it will recruit participants for observation clinical trials through its own development app, "Canceraway," starting this fall. Through this collaboration, both companies expect to contribute to the development of global cancer treatment technology and provide better treatment options for cancer patients.

ImpriMed has developed a precision medicine AI model that combines living cancer cell-based bio information and artificial intelligence (AI), helping cancer patients find the optimal anticancer drugs. Currently, the company is working with several hospitals in the U.S. and Korea to develop the service, and it has also shown successful results in treating blood-cancer drugs for pets. It has raised a total investment of $35 million (KRW 50 billion) so far.

JOWIN Co., Ltd. has developed a cancer treatment method based on traditional oriental medicine and successfully developed a natural anticancer drug using a medicinal mineral called "Woobijae(Micacine)" and has already been applied to clinical practice for several years. It uses non-toxic and side-effect-free sericite as its main raw material, and it has been confirmed through observational clinical trials that it not only treats cancer but also alleviates the side effects of anticancer drugs and boosts immunity.

 It also provides integrated care solutions that combine NK cell activation technology and high-frequency thermal therapy through partner hospitals for stage 4 and intractable cancer patients. It has recently signed a contract with Mind Cafe, which has more than 2 million members, to operate a cancer counseling service, and is growing into a cancer total platform that provides psychological counseling and mental care for cancer patients by training cancer counselors called "CanSupport."

This strategic partnership between JOWIN. and ImpriMed is expected to present a new treatment paradigm through the convergence of AI technology and traditional cancer treatment methods, and is expected to be promising news for cancer patients at home and abroad.

Source: http://www.wikileaks-kr.org/news/articleView.html?idxno=155173